Ciprofol vs Propofol for Reducing Hypoxia Incidence in ERCP

Launched by RENJI HOSPITAL · Aug 28, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring the use of a new anesthesia drug called Ciprofol compared to the standard drug, Propofol, for patients undergoing a procedure known as endoscopic retrograde cholangiopancreatography (ERCP). This procedure helps doctors look at the bile ducts and pancreas, and it often requires sedation to keep patients comfortable. Ciprofol is believed to be more effective at preventing low oxygen levels (hypoxia) during this procedure, but there isn't enough information yet about how well it works for ERCP specifically.

To participate in this trial, individuals must be between the ages of 18 and 75, have normal kidney function, and meet certain weight criteria. However, people with a history of serious neurological issues, allergies to anesthesia, or certain heart and respiratory conditions will not be eligible. If you join the study, you can expect to receive either Ciprofol or Propofol during your ERCP, and researchers will monitor your health throughout the process to see how well the anesthesia works. This trial is not currently recruiting participants, but it aims to gather valuable information that could improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients undergoing ERCP, ASA I-III
• • normal renal function
• • BMI ≥ 18kg/m 2 and ≤ 30kg/m 2
• Exclusion Criteria:
• • Previous serious cerebrovascular accidents and other neurological diseases
• • mental diseases, long-term use of drugs that affect the function of the central nervous system, benzodiazepines or opioids
• • history of anesthetic allergy
• • preoperative hypotension or preoperative SpO2 \< 90%, or chronic respiratory failure
• • patients suspected of having difficult airways
• • screening for drug addiction and alcohol abuse within the first 3 months (\> = 6standarddrinks/day)
• • patients diagnosed with severe cardiopulmonary disease, or respiratory or respiratory diseases such as sleep apnea syndrome;
• • bradycardia or atrioventricular block.
• • participate in other clinical trials within 4 weeks;
• • cognitive or communication abnormalities determined by the researchers;
• • emergent and critical conditions during the operation;
• • other conditions that the researchers believe are not suitable to participate in the study.